{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:55Z","timestamp":1790198515412,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ctrv.2020.102042","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T06:18:22Z","timestamp":1590819502000},"page":"102042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-2354","authenticated-orcid":false,"given":"Aung M.","family":"Tun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102042_b0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/358630a0","article-title":"Coley\u2019s vaccine and TNF therapy","volume":"358","author":"Brouckaert","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102042_b0010","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthopaedic J"},{"key":"10.1016\/j.ctrv.2020.102042_b0015","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.3109\/10428194.2015.1011640","article-title":"T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion","volume":"56","author":"Yang","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ctrv.2020.102042_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP \u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2020.102042_b0025","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24. 1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0030","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2020.102042_b0035","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4 + T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nature Immunol"},{"key":"10.1016\/j.ctrv.2020.102042_b0040","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0050","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/2159-8290.CD-19-0977","article-title":"Immunotransplant: preventing unintended consequences","volume":"9","author":"Ansell","year":"2019","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.ctrv.2020.102042_b0055","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2326-6066.CIR-18-0890","article-title":"The highs and lows of immune-checkpoint blockade in lymphoma","volume":"7","author":"Ansell","year":"2019","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.ctrv.2020.102042_b0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/asheducation-2017.1.618","article-title":"Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond","volume":"2017","author":"Ansell","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.ctrv.2020.102042_b0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2005-04-1510","article-title":"Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions","volume":"107","author":"Rimsza","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0070","first-page":"3904","article-title":"Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma","volume":"6","author":"Stopeck","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0075","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctrv.2020.102042_b0080","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DRlow\/\u2212 monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0090","doi-asserted-by":"crossref","first-page":"e59456","DOI":"10.1371\/journal.pone.0059456","article-title":"Soluble and membrane-bound TGF-beta-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2020.102042_b0095","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R \u03b1 facilitates IL-2 \u2212 mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0100","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.174.4.915","article-title":"Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression","volume":"174","author":"de Waal","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2020.102042_b0105","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102042_b0115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0120","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0125","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.2437_54","article-title":"Blockade of the PD-1 checkpoint with anti\u2013PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL)","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0135","doi-asserted-by":"crossref","unstructured":"Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039); 2016.","DOI":"10.1182\/blood.V128.22.183.183"},{"key":"10.1016\/j.ctrv.2020.102042_b0140","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.134_2629","article-title":"Investigating safety and preliminary efficacy of AFM13 plus pembrolizumab in patients with relapsed\/refractory hodgkin lymphoma after brentuximab vedotin failure","volume":"37","author":"Ansell","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0150","doi-asserted-by":"crossref","unstructured":"Diefenbach C, Hong F, Ambinder RF, Cohen JB, Robertson M, David KA, et al. A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412: Arms GI); 2018.","DOI":"10.1182\/blood-2018-99-115390"},{"key":"10.1016\/j.ctrv.2020.102042_b0155","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0160","first-page":"JCO-19","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0165","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Schjesvold F, Rocafiguera AO, Karlin L, Rifkin RM, Yimer HA, et al. A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185; 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.8010"},{"key":"10.1016\/j.ctrv.2020.102042_b0170","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2020.102042_b0175","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0180","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol: Offic J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ctrv.2020.102042_b0195","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-019-0233-5","article-title":"Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma","volume":"9","author":"Wang","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2020.102042_b0205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0210","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0220","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0225","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0230","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0235","first-page":"4055","article-title":"PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma","volume":"130","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0240","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor infiltrating treg cells after PD-1 blockade","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0245","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102042_b0250","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0255","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2020.102042_b0260","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.833.833","article-title":"Safety and efficacy of the combination of ibrutinib and nivolumab in patients with relapsed non-hodgkin lymphoma or chronic lymphocytic leukemia","volume":"130","author":"Younes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0270","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0280","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","article-title":"Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0285","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102042_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102042_b0295","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4049\/jimmunol.161.4.1853","article-title":"Signal-regulatory protein is selectively expressed by myeloid and neuronal cells","volume":"161","author":"Adams","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102042_b0300","doi-asserted-by":"crossref","first-page":"22719","DOI":"10.1074\/jbc.273.35.22719","article-title":"High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages","volume":"273","author":"Veillette","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2020.102042_b0305","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1182\/blood-2011-11-391367","article-title":"Is targeting of CD47-SIRP\u03b1 enough for treating hematopoietic malignancy?","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0310","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2020.102042_b0315","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0320","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.ctrv.2020.102042_b0325","first-page":"1836","article-title":"Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma","volume":"2014","author":"Goto","year":"1990","journal-title":"Eur J Cancer (Oxford, Engl)"},{"key":"10.1016\/j.ctrv.2020.102042_b0330","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102042_b0335","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf","year":"2013","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.ctrv.2020.102042_b0340","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102042_b0345","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res: Offic J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0350","article-title":"TTI-621 (SIRP\u03b1Fc), an immune checkpoint inhibitor blocking the CD47 \u201cDo Not Eat\u201d signal, induces objective responses in patients with advanced, relapsed\/refractory diffuse large B-cell lymphoma (DLBCL)","volume":"130","author":"Ansell","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0355","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ejca.2018.07.297","article-title":"Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed\/refractory mycosis fungoides and Sezary syndrome: interim results of a multicenter Phase 1 trial","volume":"101","author":"Querfeld","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102042_b0360","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0365","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.102042_b0370","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2020.102042_b0375","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0380","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3-bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102042_b0385","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4501.4501","article-title":"A novel CD20xCD3 bispecific fully human antibody induces potent anti-tumor effects against B cell lymphoma in mice","volume":"124","author":"Varghese","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0395","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2020.102042_b0400","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.621.621","article-title":"Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy","volume":"128","author":"Bannerji","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0405","doi-asserted-by":"crossref","unstructured":"Topp MS, Arnason J, Advani R, Brown JR, Allan J, Ansell S, et al. Emerging clinical activity of REGN1979, an anti-CD20 X anti-CD3 bispecific antibody (AB), in patients (PTS) with relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (B-NHL): S868. HemaSphere 2019;3.","DOI":"10.1097\/01.HS9.0000561752.46264.f3"},{"key":"10.1016\/j.ctrv.2020.102042_b0410","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1836.1836","article-title":"CD20 Tcb (RG6026), a novel " 2: 1" T cell bispecific antibody for the treatment of B cell malignancies","volume":"128","author":"Bacac","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0415","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110207","article-title":"CD20-Tcb (RG6026), a Novel \u201c2:1\u201d format T-cell-engaging bispecific antibody, induces complete remissions in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: preliminary results from a phase I first in human trial","volume":"132","author":"Hutchings","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0420","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0425","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7570","article-title":"The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089\/NCT03038672)","volume":"37","author":"Villasboas","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0435","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s13063-018-2996-6","article-title":"RIVA\u2013a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial","volume":"19","author":"Lim","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2020.102042_b0440","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps3108","article-title":"A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed\/refractory B-cell malignancies","volume":"31","author":"Kohrt","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0445","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","article-title":"Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia","volume":"18","author":"Vitale","year":"2012","journal-title":"Clin Cancer Res: Offic J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0450","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/jco.2014.32.15_suppl.3024","article-title":"Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies","volume":"32","author":"Ansell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0455","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","article-title":"PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8(+) T-cell-driven antitumor immunity","volume":"24","author":"Buchan","year":"2018","journal-title":"Clin Cancer Res: Offic J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0460","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2009-05-223958","article-title":"Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion","volume":"114","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0465","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2003-06-2184","article-title":"Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo","volume":"103","author":"Wilcox","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102042_b0470","series-title":"Proceedings of the national academy of sciences","first-page":"7551","author":"Weigelin","year":"2015"},{"key":"10.1016\/j.ctrv.2020.102042_b0475","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2008.26.15_suppl.3007","article-title":"Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)","volume":"26","author":"Sznol","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0480","doi-asserted-by":"crossref","first-page":"e1296996","DOI":"10.1080\/2162402X.2017.1296996","article-title":"S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity","volume":"7","author":"Zhang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2020.102042_b0485","first-page":"O7","article-title":"Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies","volume":"4","author":"Massarelli","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102042_b0490","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102042_b0495","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hon.2438_127","article-title":"A Phase I study of utomilumab (PF-05082566), a 4\u20131BB\/CD137 Agonist, in combination with rituximab in patients with CD20+ non-Hodgkin\u2019s Lymphoma","volume":"35","author":"Gopal","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0500","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s Lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0505","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"De Vos","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102042_b0510","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10428194.2012.710328","article-title":"Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma","volume":"54","author":"Forero-Torres","year":"2013","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ctrv.2020.102042_b0515","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3109\/10428194.2015.1007504","article-title":"Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb","volume":"56","author":"Fayad","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ctrv.2020.102042_b0520","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:58Z","timestamp":1759656178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":104,"alternative-id":["S0305737220300803"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102042","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102042"}}